Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies

Epilepsia - Tập 51 Số 6 - Trang 1069-1077 - 2010
Patrick Kwan1, Alexis Arzimanoglou2, Anne T. Berg3, Martin J. Brodie4, W. Allen Hauser5, Gary W. Mathern6, Solomon L. Moshé7, Emilio Perucca8, Samuel Wiebe9, Jacqueline A. French10
1Chinese University of Hong Kong
2Institut National de la Santé et de la Recherche Médicale
3Northern Illinois University
4Western Infirmary
5Columbia University
6University of California at, Los Angeles
7Yeshiva University
8University of Pavia
9University of Calgary
10New York University

Tóm tắt

Summary

To improve patient care and facilitate clinical research, the International League Against Epilepsy (ILAE) appointed a Task Force to formulate a consensus definition of drug resistant epilepsy. The overall framework of the definition has two “hierarchical” levels: Level 1 provides a general scheme to categorize response to each therapeutic intervention, including a minimum dataset of knowledge about the intervention that would be needed; Level 2 provides a core definition of drug resistant epilepsy using a set of essential criteria based on the categorization of response (from Level 1) to trials of antiepileptic drugs. It is proposed as a testable hypothesis that drug resistant epilepsy is defined as failure of adequate trials of two tolerated, appropriately chosen and used antiepileptic drug schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom. This definition can be further refined when new evidence emerges. The rationale behind the definition and the principles governing its proper use are discussed, and examples to illustrate its application in clinical practice are provided.

Từ khóa


Tài liệu tham khảo

10.1093/brain/awh200

Arzimanoglou A, 2008, Progress in Epileptic Disorder (Volume 7): Drug‐resistant epilepsies, 1

10.1111/j.1528-1157.1998.tb01361.x

10.1212/WNL.52.7.1306

10.1212/WNL.56.11.1445

10.1002/ana.20852

10.1002/ana.21642

10.1002/ana.21166

10.1016/j.yebeh.2008.02.006

10.1212/01.wnl.0000219729.08924.54

10.1016/S0140-6736(00)02799-9

10.1111/j.1528-1157.1994.tb02491.x

Hanley JA, 1983, If nothing goes wrong, is everything alright?, JAMA, 259, 1743, 10.1001/jama.1983.03330370053031

10.1002/ana.410280516

10.1111/j.1528-1157.1996.tb00006.x

10.1212/01.wnl.0000259411.78423.50

Kahane P, 2008, Drug‐resistant Epilepsies. Progress in Epileptic Disorders

10.1002/cpt1977213247

10.1056/NEJM200002033420503

10.1046/j.1528-1157.2001.04501.x

Kwan P, 2006, The Treatment of Epilepsy: Principles and Practice, 983

10.1093/ajhp/52.4.379

10.1016/j.eplepsyres.2005.02.009

10.1002/ana.21064

10.1111/j.1528-1157.2000.tb00238.x

10.1111/j.1468-1331.2006.01215.x

10.2165/00023210-199810030-00002

10.2165/00023210-200115080-00004

10.1016/j.yebeh.2003.10.017

10.1212/01.wnl.0000286959.22040.6e

10.1111/j.0013-9580.2004.44203.x

10.1212/01.WNL.0000151957.80848.0E

10.1002/ana.21131

10.1016/S0920-1211(98)00106-5

10.1093/brain/awl316

10.1016/S0140-6736(95)92470-1

10.4065/71.11.1105

10.1111/j.1528-1167.2007.01133.x

10.1016/S0920-1211(99)00016-9

World Health Organization, 1972, International Drug Monitoring: the Role of National Centres, 498

World Health Organization Collaborating Centre for Drug Statistics Methodology. (2008)About the ATC/DDD system. Accessed December 1 2008 athttp://www.whocc.no/atcddd/.